| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | 0.077 | 0.05 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.15 | 0.05 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.05 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.092 | 0.05 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.074 | 0.05 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | -0.075 | 0.05 |